

EXHIBIT 2

1 IN THE UNITED STATES DISTRICT COURT
2 FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA
3 CHARLESTON DIVISION

4 IN RE: ETHICON, INC., Master File No. 2:12-MD-02327
5 PELVIC REPAIR SYSTEM MDL 2327
6 PRODUCTS LIABILITY
7 LITIGATION

8 THIS DOCUMENT RELATES TO JOSEPH R. GOODWIN
9 ALL CASES U.S. DISTRICT JUDGE

10 CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

11 - - -

12 June 19, 2015

13 - - -

14 Videotaped deposition of LAURA ANGELINI,
15 held at Rogers Towers, 1301 Riverplace Boulevard, Suite
16 1500, Jacksonville, Florida 32207, commencing at 8:14 a.m.,
17 on the above date before Celeste O. Werkheiser, RMR, CRR.

18 - - -

19 GOLKOW TECHNOLOGIES, INC.
20 877.370.3377 ph|917.951.5672 fax
21 deps@golkow.com

1 APPEARANCES:

2 Andrew N. Faes, Esquire
Wagstaff & Cartmell, LLP
3 4740 Grand Avenue, Suite 300
Kansas City, Missouri 64112
4 (816) 701-1100
afaes@wcllp.com

5 Attorney for Plaintiff
6 Adam M. Slater, Esquire
(Appeared by phone)
7 Mazie Slater Katz & Freeman, LLC
103 Eisenhower Parkway, 2nd Floor
8 Roseland, New Jersey 07068
(973) 228-9898
9 aslater@mskf.net
Attorney for Plaintiff

10
Calle M. Mendenhall, Esquire
11 (Appeared by phone)
Freese & Goss, PLLC
12 Regions Harbert Plaza
1901 6th Avenue North
13 Suite 3120
Birmingham, Alabama 35203
14 (205) 871-4144
calle@freeseandgoss.com

15 Attorney for Plaintiff
16 Ebiho T. Ahonkhai, Esquire
(Appeared by phone)
17 Kline & Specter, P.C.
1525 Locust Street
18 18th Floor
Philadelphia, Pennsylvania 19102
19 (215) 772-0416
Ebiho.Ahonkhai@KlineSpecter.com

20 Attorney for Plaintiff
21 Cathryn R. Paton, Esquire
(Appeared by phone)
22 Thiebaud Remington Thornton Bailey LLP
Two Energy Square
23 4849 Greenville Avenue, Suite 1150
Dallas, Texas 75206
24 (214) 954-2224
cpaton@trtblaw.com

25 Attorney for Teresa Kowalczyk, M.D.

1 APPEARANCES: (Continued)

2 Jacqueline E. Fusco, Esquire
(Appeared by phone)

3 Tooher Wocl Leydon, LLC
80 Fourth Street

4 Stamford, Connecticut 06905
(203) 517-0456

5 Attorney for Plaintiff

6 William M. Gage, Esquire
Butler Snow, LLP

7 Renaissance at Colony Park
1020 Highland Colony Parkway

8 Suite 1400
Ridgeland, Mississippi 39157

9 (601) 948-5711
william.gage@butlersnow.com

10 Attorney for Johnson & Johnson

11 Maha M. Kabbash, Esquire
Riker Danzig Scherer Hyland Perretti, LLP

12 Headquarters Plaza
One Speedwell Avenue

13 Morristown, New Jersey 07962-1981
(973) 538-0800

14 mkabbash@riker.com

Attorney for Johnson & Johnson

15

16

17

18 VIDEOGRAPHER:

19 David Lane

20

21

22

23

24

25

1 surgeons that any of your mesh products had a short-term
2 foreign body reaction, and it ended and was not ongoing
3 and chronic if, in fact, the foreign body reaction would
4 continue. You couldn't want to misstate the truth,
5 right?

6 MR. GAGE: Objection.

7 THE WITNESS: I'm not sure that I understand
8 your question, sir. Sorry. Can you rephrase your
9 question?

10 BY MR. SLATER:

11 Q No, it doesn't matter.

12 All right. Let's go to the next document,
13 which is -- November 20, 1998 is the first e-mail.

14 MR. FAES: Handing the witness what's been
15 marked as Exhibit T-3731, which starts with
16 ETH.MESH.12009066.

17 (Exhibit T-3731 marked.)

18 BY MR. SLATER:

19 Q Looking at this exhibit, 3731, let's go to the
20 bottom of the first page. It's an e-mail regarding the
21 Medscand contract, and it's dated November of 1998. Do
22 you see that?

23 A Yes.

24 Q And if we go up above, we see that this chain
25 of e-mails, you actually wrote the e-mail in the middle

1 of the first page, and you were one of the recipients of
2 the one at the top. So you received these e-mails,
3 correct?

4 A Yes. Correct.

5 Q And e-mails like this, that's something that
6 was exchanged in the ordinary day-to-day business when
7 you were working here at Ethicon, correct?

8 A Can I read it to be able to answer your
9 question? Give me a minute.

10 Yeah, well, I wouldn't qualify as a regular
11 because this refers in particular to a very specific
12 transaction between Ethicon and Medscand was the -- at
13 that time, the owner of the TVT technology.

14 So I wouldn't qualify this as a normal e-mail
15 in a normal day of life because it refers to a -- you
16 know, a very particular event, which is the acquisition
17 or the licensing of a new technology.

18 Q Ms. Angelini, you see these e-mails in front of
19 you?

20 A Yes.

21 Q Your company, in its ordinary business, when
22 you would communicate with other people you would use
23 e-mails like these, correct?

24 A Oh, yes.

25 Q And that's what these e-mails are, is you and

1 other people in your company communicating within the
2 company about company business, correct?

3 A Correct.

4 Q And if we go to the second page, which is part
5 of the e-mail from Mark Dumenil, he talks at the very
6 bottom about purchasing the manufacturing rights of TVT
7 from Medscand for 22 million dollars. That's what's
8 documented there, correct?

9 A Correct.

10 Q If we flip to the first page, at the very top
11 there's an e-mail from Rodrigo Bianchi, and you're one
12 of the people who got that e-mail. Do you see that?

13 A Yes.

14 Q November 20, 1998 is the date, right?

15 A Yes.

16 Q And in this e-mail, Rodrigo Bianchi -- and who
17 is he?

18 A He was the Vice President at that time, in '98,
19 was Vice President for Gynecare and Mitek for Europe.

20 Q And he says in this e-mail, talking about
21 Professor Ulmsten and Medscand, that he doesn't see any
22 reason why they should be going to Somerville -- and
23 that would be Ethicon's offices, their U.S. headquarters
24 in Somerville, New Jersey, right?

25 A Right.

1 Q It says: "Many times Ulmsten" -- and let me
2 just stop there. Ulmsten is the surgeon who actually
3 developed and created the TVT, correct?

4 A Correct.

5 Q It says: "Many times Ulmsten tried to
6 interfere in marketing issues. We clarified that
7 is not his job." That's what's documented here,
8 correct?

9 A Yeah. That's what Mr. Bianchi said in this
10 e-mail.

11 Q And he then indicates, a little further down:
12 "TVT is a European project, and Laura is the global
13 project leader. Let's respect roles and
14 responsibilities."

15 He's talking about you as being the global
16 project leader for the TVT, correct?

17 A Yes.

18 Q Global means the entire world, right?

19 A Well, in that time, that context meant my
20 primary responsibility was, you know, the responsibility
21 for the European business.

22 Because this product was invented in Europe and
23 was originally manufactured by Medscand, I had
24 additional responsibility of coordinating activities
25 globally, which included me being in contact with my